PARP1 and tuberculosis: Considering the fact that new regimens, such as bedaquiline-pretomanid-linezolid (BPaL), that are free of the traditional first-line anti-TB drugs are now used for the treatment of drug-resistant TB, an argument can be made that PARP1 inhibition may add a measure prevention against tissue damage69.